Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study is a prospective non-randomized multi-center feasibility clinical trial to establish the safety and efficacy of the Nucel® allograft tissue for use in lumbar interbody fusion procedures.
Two hundred non-randomized subjects will participate in the study at up to ten clinical sites in the United States. Participants will be between 18 and 75 years of age. All subjects will have been established with lumbar spine disease at one or two levels of the lumbar spine that requires lumbar interbody fusion procedure as per the opinion of the treating surgeon. The diseases included in the study are spondylosis, degenerative disc disease and spondylolisthesis. All subjects who meet the inclusion criteria and do not meet the exclusion criteria and who elect to participate and sign the informed consent will be included in the study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Nucel treatment group | Other | One or two level lumbar interbody fusion surgery with Nucel |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| One or two level lumbar interbody fusion surgery | Procedure | One or two level lumbar interbody fusion surgery with allograft derived from human amnion and amniotic fluid. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Fusion rate using non-contrast CT of the lumbar spine | Fusion will be assessed 2 years by independent radiologist using alpha-numeric grading scale to quantify bone growth and supplemental fixation quality | 2 years |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Neurologic Exam | Physician conducted neurological exam | 2 years |
| Visual Analogue Scale | Patient health outcome survey | 2 years |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pierce Nunley, MD | Spine Institute of Louisiana | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Florida Orthopaedic Insitute | Tampa | Florida | 33609 | United States | ||
| Spine Institute of Louisiana |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D055959 | Intervertebral Disc Degeneration |
| D013168 | Spondylolisthesis |
| D055009 | Spondylosis |
| ID | Term |
|---|---|
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D013169 | Spondylolysis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Nucel | Other | Allograft derived from human amnion and amniotic fluid |
|
| Oswestry Low Back Pain Disability Index | Patient health outcome survey | 2 years |
| SF-12 health survey | Patient health outcome survey | 2 years |
| Shreveport |
| Louisiana |
| 71101 |
| United States |
| Carolina Neurosurgery & Spine | Charlotte | North Carolina | 28204 | United States |